Article may be outdated

This article is 7 days old. Some details may have changed since publication.

The Guardian·4 min read·medium

Pharma firms’ focus on weight-loss drugs could put insulin supply at risk, experts warn

J
Julia Kollewe
Pharma firms’ focus on weight-loss drugs could put insulin supply at risk, experts warn
✦AI Summary

Experts warn that pharmaceutical companies are prioritizing lucrative weight-loss drugs like Ozempic and Mounjaro over essential diabetes treatments like insulin. This shift could lead to supply shortages for patients in lower-income countries.

Why it matters

The prioritization of high-profit lifestyle medications over life-saving chronic disease treatments raises significant ethical and public health concerns.

✦Dive DeeperCreate a free account to unlock

Pharma firms can charge far higher prices for GLP-1 drugs including Mounjaro, Wegovy and Ozempic than for diabetes treatments such as insulin. Pharma firms can charge far higher prices for GLP-1 drugs including Mounjaro, Wegovy and Ozempic than for diabetes treatments such as insulin. Pharmaceuticals industry Pharma firms’ focus on weight-loss drugs could put insulin supply at risk, experts warn GLP-1 products such as Ozempic and Mounjaro spread but many in poorer countries struggle to get basic diabetes treatment

Prefer the Guardian on Google The gold rush into GLP-1 weight-loss drugs risks diverting pharmaceutical firms’ attention away from diabetes treatments such as insulin, the head of the Access to Medicine Foundation has warned.

Continue reading on Headlinne

Create a free account to read the full article.

Read full article →
healthbusinesseconomy
✦

Get smarter about the news

Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.

Create free account

Already have an account? Sign in